Keros Therapeutics (KROS) Misses Q2 EPS by 5c
Keros Therapeutics (NASDAQ: KROS) reported Q2 EPS of ($1.45), $0.05 worse than the analyst estimate of ($1.40).
For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.
Keros Therapeutics (NASDAQ: KROS) reported Q2 EPS of ($1.45), $0.05 worse than the analyst estimate of ($1.40).
For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.